Short Duration Treatment of Non-severe Community Acquired Pneumonia

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), who responded well to 3 days of beta-lactamin treatment (3GC or A/AC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Versailles Hospital
• Treatments: Amoxicillin-Potassium Clavulanate Combination; beta-Lactams; Clavulanic Acid; Clavulanic Acids; Lactams

Criteria

Inclusion Criteria:

• Subject must be 18 years old or over.

• admitted three days before for Community Acquired Pneumonia (CAP) defined by at least one clinical sign of pneumonia (dyspnea, cough, mucopurulent sputum, crackling sound on lungs) associated with a temperature >38°C on admission, and a new infiltrate consistent with pneumonia on chest x-ray, who responded favorably to 3 days of treatment with β-lactams (third generation injectable cephalosporin or amoxicillin-clavulanate)

• able to take oral medication.

• has given its informed consent.

Exclusion Criteria:

• Creatinin < 30ml/min

• History of jaundice / hepatic impairment associated with amoxicillin / clavulanic acid

• History of hypersensitivity to beta-lactam

• Presence of complications or severity of pneumonia (abscess , significant pleural effusion, severe chronic respiratory failure , septic shock, respiratory condition requiring the passage resuscitation).

• Known immunocompromised terrain ( asplenia , neutropenia, agammaglobulinemia , immunosuppressants, graft corticosteroids , myeloma , lymphoma, known HIV , sickle cell anemia , CHILD C cirrhosis).

• Antibiotic treatment exceeding 24 hours prior admission.

• Suspected atypical bacteria requiring combined antibiotics therapy .(Subjects who received a single dose of macrolides or fluoroquinolones emergency will not be excluded) .

• Legionella suspected on clinical, biological and radiological criteria .

• Subjects with clinical or epidemiological environment leading to suspect a healthcare-associated pneumonia with antibiotic resistant pathogen.

• Suspicion of pneumonia by aspiration.

• Intercurrent infection requiring antibiotic treatment.

• Pregnant women .

• Breastfeeding .

• Allergy to antibiotics in use.

• Life expectancy <1 month .

• Subject without health insurance.

• Subjects without home adress